• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aradigm Corp.

Cash-strapped Aradigm declares bankruptcy

February 19, 2019 By Sarah Faulkner

Aradigm

Aradigm Corp. (NSDQ:ARDM) announced last week that it’s officially declaring bankruptcy. Strapped for cash, the Calif.-based company resigned to filing for Chapter 11 protection after it couldn’t confirm funding from its primary investor and partner, Grifols. “Aradigm intends to commence a process to sell substantially all of its assets to an interested party, subject to Bankruptcy […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Aradigm Corp.

FDA wants more clinical data for Aradigm’s inhaled lung drug

January 29, 2018 By Sarah Faulkner

Aradigm

Aradigm Corp. (NSDQ:ARDM) shares tumbled today after the company reported that the FDA denied its application for an inhaled drug designed to treat non-cystic fibrosis bronchiectasis patients with chronic lung infections. The agency’s complete response letter reportedly highlighted an array of concerns with the initial application, including product quality and the company’s clinical data. Specifically, the […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: Aradigm Corp.

Aradigm lands NIH grant for inhaled, liposomal products

August 15, 2017 By Sarah Faulkner

Aradigm

Aradigm Corp. (NSDQ:ARDM) said today that the National Institute of Allergy and Infectious Diseases and the NIH awarded the company a grant to study the treatment of pulmonary non-tuberculous mycobacteria infections with Aradigm’s inhaled liposomal ciprofloxacin products, Linhaliq and Lipoquin. The two-year grant is worth approximately $972,000, according to the Hayward, Calif.-based company. The Phase II […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Aradigm Corp.

Late-stage trial fails for Aradigm’s inhaled antibiotic

December 1, 2016 By Sarah Faulkner

Aradigm

Aradigm Corp. (NSDQ:ARDM) said today that its inhaled antibiotic failed in a late-stage clinical trial, sending the Hayward, Calif.-based company’s stock down -54% in premarket trading. Pulmaquin is a once-daily formulation containing ciprofloxacin, a widely prescribed broad-spectrum antibiotic. The inhaled drug was being tested to treat patients with non-cystic fibrosis bronchiectasis (non-CF BE) who have chronic […]

Filed Under: Clinical Trials, Featured, Respiratory Tagged With: Aradigm Corp.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS